Halozyme Therapeutics (HALO) Other Non-Current Liabilities (2013 - 2026)

Halozyme Therapeutics (HALO) has reported Other Non-Current Liabilities for 14 consecutive years, with $106.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 88.62% year-over-year to $106.4 million; the TTM figure through Mar 2026 stood at $106.4 million (up 88.62% YoY), while the FY2025 annual figure was $113.9 million, up 107.94% from the prior year.
• Other Non-Current Liabilities eased to $106.4 million in Q1 2026 per HALO's latest filing, from $113.9 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $130.0 million in Q2 2022 and bottomed at $171000.0 in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $50.6 million across 5 years, with a median of $37.7 million in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities slumped 93.91% — and 2023, when it surged 17194.15%.
• Halozyme Therapeutics' Other Non-Current Liabilities stood at $15.5 million in 2022, then soared by 143.8% to $37.7 million in 2023, then jumped by 45.17% to $54.8 million in 2024, then surged by 107.94% to $113.9 million in 2025, then fell by 6.51% to $106.4 million in 2026.
• Business Quant data shows HALO's Other Non-Current Liabilities at $106.4 million in Q1 2026, $113.9 million in Q4 2025, and $71.8 million in Q3 2025.